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Abstract: In patients undergoing percutaneous coronary intervention (PCI) for acute coronary 
syndrome (ACS), both periprocedural acute myocardial infarction and bleeding complications 
have been shown to be associated with early and late mortality. Current standard antithrom-
botic therapy after coronary stent implantation consists of lifelong aspirin and clopidogrel 
for a variable period depending in part on the stent type. Despite its well-established efficacy 
in reducing cardiac-related death, myocardial infarction, and stroke, dual antiplatelet therapy 
with aspirin and clopidogrel is not without shortcomings. While clopidogrel may be of little 
beneficial effect if administered immediately prior to PCI and may even increase major 
bleeding risk if coronary artery bypass grafting is anticipated, early discontinuation of the 
drug may result in insufficient antiplatelet coverage with thrombotic complications. Optimal 
and rapid inhibition of platelet activity to suppress ischemic and thrombotic events while 
minimizing bleeding complications is an important therapeutic goal in the management of 
patients undergoing percutaneous coronary intervention. In this article we present an overview 
of the literature on clinical trials evaluating the different aspects of antithrombotic therapy in 
patients undergoing PCI and discuss the emerging role of these agents in the contemporary 
era of early invasive coronary intervention. Clinical trial acronyms and their full names are 
provided in Table 1.
Keywords: acute coronary syndrome, percutaneous coronary intervention, aspirin, clopidogrel, 
glycoprotein IIb/IIIa inhibitors, bivalirudin
Antiplatelet agents
Aspirin
Aspirin irreversibly acetylates cyclooxygenase subtype 1 found in platelets and effec-
tively blocks the production of the potent aggregatory agent thromboxane A2. Aspirin 
is an essential drug in every PCI setting.
In an observational analysis of the PCI-CURE study consisting of 2,658 patients 
with ACS undergoing PCI stratified into three aspirin dose groups . 200 mg (high, 
n = 1,064), 101–199 mg (moderate, n = 538), and ,100 mg (low, n = 1,056), Jolly et al1 
demonstrated similar rates of cardiovascular death, myocardial infarction (MI), or stroke 
among the three aspirin groups, whereas the rate of major bleeding was increased in those 
receiving high dose aspirin (Hazard ratio of high- vs low-dose 2.05, P = 0.009). Notably, 
however, the risk of major bleeding was increased in high- compared to   moderate- and 
low-dose groups [HR: high- vs low-dose 2.05 (1.20–3.50), and   moderate- vs low-dose 
0.78 (0.34–1.77)]. Similarly, the net adverse clinical events (death, MI, stroke, major 
bleeding) favored low- over high-dose aspirin (8.4% vs 11.0%, HR 1.31, P = 0.056). Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Nonetheless, it should be noted that several limitations 
  intrinsic to any observational study exist.
The CURRENT-OASIS-7 was the first large scale, mul-
ticenter, multinational, randomized factorial trial designed to 
simultaneously evaluate the efficacy and safety of a higher 
loading and maintenance dose of clopidogrel compared with 
the standard-dose regimen and high-dose ASA compared 
with low-dose ASA in patients with ACS, UA/NSTEMI, and 
STEMI, undergoing angiography with intended PCI.2
More than 25,000 patients were randomized in a 2 × 2 
factorial design to receive high-dose or standard-dose clopi-
dogrel (600 mg clopidogrel loading dose followed by 150 mg 
daily for 7 days, then 75 mg daily for high-dose regimen 
(n = 12,508); 300 mg clopidogrel loading dose followed 
by 75 mg daily for standard-dose regimen (n = 12,579), 
respectively). Within each group (ie, high- versus low-dose 
clopidogrel), patients were further randomized to receive 
high-dose or low-dose ASA (300–325 mg for high-dose; 
75–100 mg for low-dose). The primary outcome was first 
occurrence of any component of cardiovascular death, MI, or 
stroke through 30 days. The safety outcome was the specific 
CURRENT definition of major bleeding through 30 days.
The aspirin analysis showed no difference in the primary 
outcome between the low- and high-dose aspirin groups 
Table 1 Study acronyms and their respective clinical trial full names (in alphabetical order)
Acronyms Clinical trial full names
ACe Abciximab and Carbostent evaluation
ACUiTY Acute Catheterization and Urgent intervention Triage Strategy
ADMiRAL Abciximab Before Direct angioplasty and stenting in Myocardial infarction Regarding Acute and Long-term Follow-up
ARMYDA-2 The Antiplatelet Therapy for Reduction of Myocardial Damage during Angioplasty – 2nd edition
ASPiRe Arixtra Study in Percutaneous Coronary intervention
ATOLL Acute STeMi Treated with Primary Angioplasty and intravenous Lovenox or Unfractionated Heparin
BRiDGe Maintenance of Platelet inhibition with cangreLor after discontinuation of Thienopyridines in Patients Undergoing surgery
CHAMPiON-PCi Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet inhibition-percutaneous Coronary
intervention
CHAMPiON- Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet inhibition (Platform)
PLATFORM
CReDO Reduction of events during Observation
CURReNT/OASiS-7 Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent eveNTs/Optimal Antiplatelet Strategy for interventions
DiSPeRSe Dose Confirmation Study Assessing Anti-platelet Effects
ePiC evaluation of 7e3 for the Prevention of ischemic Complications
eSPRiT enhanced Suppression of the Platelet iib/iiia Receptor with integrilin Therapy
HORiZONS-AMi Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial infarction
iMPACT-ii integrilin to Minimize Platelet Aggregation and Coronary Thrombosis
iSAR intracoronary Stenting and Antithrombotic Regimen
iSAR-CHOiCe intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for immediate Clopidogrel effect
iSAR-ReACT intracoronary Stenting and Antithrombotic Regimen-Rapid early Action for Coronary Treatment
MATe A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy
MULTiSTRATeGY MULTIcenter Evaluation of Single High-dose Bolus Tirofiban versus Abciximab with Sirolimus Eluting STEnt or Bare Metal 
Stent in Acute Myocardial infacrtion
OASiS-5 The Fifth Organization to Assess Strategies in Acute ischemic Syndromes
OASiS-6 The Sixth Organization to Assess Strategies in Acute ischemic Syndromes
ON-TiMe-2 Ongoing Tirofiban in Myocardial Infaction Evaluation 2
PCi-CURe Percutaneous coronary intervention-Clopidogrel in Unstable angina to prevent Recurrent events
PLATO A Study of Platelet inhibition and Patient Outcomes
RePLACe-2 Randomized evaluation in Percutaneous Coronary intervention Linking Angiomax to Reduced Clinical events-2
SYNeRGY Safety and efficacy of enoxaparin versus unfractionated heparin in patients with non-ST segment elevation acute coronary 
syndromes who receive tirofiban and aspirin
TACTiCS-TiMi 18 Treat Angina with Aggrastat and Determine Cost of Therapy with an invasive or Conservative Strategy-Thrombolysis in 
Myocardial infarction 18
TiMi iiiB Thrombolysis in Myocardial ischemia
TRiLOGY A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects with Unstable Angina/ 
Non-ST-elevation Myocardial infarction who Are Medically Managed
TRiTON-TiMi 38 Trial to Assess improvement in Therapeutic Outcomes by Optimizing Platelet inhibition with Prasugrel-Thrombolysis in 
Myocardial infarction
vANQwiSH veterans Affairs Non-Q-wave infarction Strategies in-HospitalDrug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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among the overall patient cohort, the PCI subgroup, and 
the no PCI subgroup. There was also no difference in stent 
thrombosis or increase in bleeding using the CURRENT 
major or severe bleeding and TIMI major bleeding criteria. 
In the clopidogrel analysis, there was no significant difference 
in the primary composite outcome for the overall population 
between the high- and standard-dose clopidogrel (4.2% vs 
4.4% respectively; hazard ratio [HR] 0.95; P = 0.37), and no 
statistically significant benefit in each individual component 
of the primary outcome. Conversely, the PCI subgroup had 
a significant reduction in the primary composite outcome 
in the high- vs standard-dose clopidogrel (4.5% vs 3.9%; 
HR 0.85; P = 0.036) and reduction in definite stent thrombo-
sis in those who received a stent (0.7% vs 1.2%; P = 0.001). 
Both the overall population and PCI subgroup with high-dose 
clopidogrel had statistically significant increased CURRENT 
major and severe bleeding but not TIMI major bleeding, fatal 
bleeding, intracranial bleeding, or CABG-related bleeding. 
Within the high aspirin cohort, the primary efficacy event 
rate was lower with the high-dose clopidogrel vs standard-
dose clopidogrel group (4.6% vs 3.8%, HR 0.83, P = 0.036). 
There was no difference seen between the high- vs   standard- 
dose clopidogrel group within the low aspirin cohort (4.2% vs 
4.5%, HR 1.07; P = 0.42). With respect to major bleeding, 
the interaction between aspirin and clopidogrel did not reach 
statistical significance (P = 0.099).
The trial showed no clinical benefit of high-dose aspirin 
or clopidogrel for the entire study group with the exception 
of the high-dose clopidogrel PCI subgroup who had signifi-
cantly reduced ischemic events and stent thrombosis at the 
cost of increased bleeding.
Aspirin current status
The American College of Cardiology and American Heart 
Association (ACC/AHA) guidelines advocate chewing aspirin 
(162–325 mg) by patients who have not taken aspirin before 
presenting with an ST elevation myocardial infarction 
(STEMI). Post-PCI STEMI patients should continue aspirin 
162–325 mg daily for at least 1 month after bare metal stent 
(BMS) implantation, 3 months after sirolimus-eluting stent 
(SES) implantation, and 6 months after paclitaxel-eluting 
stent (PES) implantation. Thereafter, aspirin is continued 
indefinitely at a dose of 75 mg to 162 mg daily (Class I).
Patients with unstable angina (UA) or non-ST elevation 
myocardial infarction (NSTEMI) should receive aspirin as 
soon as possible after hospital presentation and be maintained 
on aspirin indefinitely (Class I).3
Thienopyridines
The thienopyridines are platelet P2Y12 receptor antagonists 
that irreversibly inhibit adenosine diphosphate (ADP)-
induced platelet aggregation. Aspirin and thienopyridine 
combination therapy has been shown to have synergistic 
antiplatelet effect and has become standard treatment for 
the prevention of ischemic events in patients with ACS and 
in those undergoing PCI.
Ticlopidine
Ticlopidine is a first generation thienopyridine that has 
largely been replaced by clopidogrel. Studies suggest that 
clopidogrel has a more favorable side effect profile and 
is a safe and effective alternative to ticlopidine. Although 
uncommon, serious ticlopidine-associated adverse effects 
include neutropenia, thrombocytopenia, thrombotic throm-
bocytopenic purpura, rash, hepatic cholestasis, and in rare 
cases, aplastic anemia, pancytopenia, and agranulocytosis.
Clopidogrel
The beneficial effects of aspirin and clopidogrel combination 
therapy in the prevention of major ischemic events after PCI 
have been well described. Nonetheless, studies in which the 
optimal dosing and timing for clopidogrel   treatment before 
PCI have been evaluated have yielded variable and   conflicting 
results owing in part to the broad range in the duration of 
pretreatment (hours to days), wide interindividual variability 
in the inhibitory response to clopidogrel, and differences in 
study designs. The following section contains a discussion 
of selected clinical trials evaluating the effectiveness of 
clopidogrel pretreatment in patients undergoing PCI.
The PCI-CURE trial was among the first study in 
which the beneficial effect of clopidogrel pretreatment in 
patients undergoing PCI was demonstrated.4 Of more than 
12,000 patients with non-ST elevation ACS in the CURE study 
who were randomly assigned to receive either   clopidogrel or 
placebo, 1,313 in the clopidogrel- and 1,345 in the placebo-
treated groups underwent PCI. A loading dose of clopidogrel 
300 mg or matching placebo was given a median of 10 days 
before PCI. After PCI, more than 80% of patients in both 
groups received open-labeled thienopyridine for 4 weeks, 
after which the study drug was restarted and continued for a 
mean of 8 months. Compared to placebo, clopidogrel reduced 
the risk of composite primary endpoint (cardiovascular death, 
MI, or urgent revascularization by 30 days after PCI) by 
nearly one third (RR 0.70, P = 0.03). The beneficial effect of 
clopidogrel was seen before PCI, in the 4 weeks after PCI, Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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and in the months thereafter when clopidogrel was continued 
long-term. There was no significant difference in major bleed-
ing between the two treatment groups at last follow-up (3–12 
months after randomization).
In contrast to the PCI-CURE study, results gained from 
the CREDO trial demonstrated that clopidogrel pretreatment 
did not significantly reduce adverse cardiac events at 28 days.5 
However, subgroup analysis suggested that at least 6 hours of 
pretreatment is necessary to demonstrate a beneficial effect 
of clopidogrel. In this study, aspirin-treated patients who 
underwent elective PCI were randomized to receive 300 mg 
clopidogrel loading dose (n = 1,053) or matching placebo 
(n = 1,063) 3–24 hours before PCI followed by clopidogrel 
75 mg/day through day 28 in each arm. Thereafter, patients 
in the loading dose group received clopidogrel 75 mg/day 
through month 12 whereas those in the control group received 
a placebo. In the overall cohort, administration of a clopidogrel 
loading dose did not significantly reduce the combined risks 
of death, MI, or urgent target-vessel revascularization at 
28 days. However, subgroup analysis demonstrated that among 
patients in whom the study drug was initiated at least 6 hours 
prior to PCI, those randomized to clopidogrel experienced a 
38.6% relative reduction in the combined end points that was 
of borderline statistical significance (P = 0.051). However, 
post hoc analysis of the CREDO trial demonstrated that the 
  difference in outcomes between placebo and   clopidogrel 
  pretreated patients was not significant until at least 15 hours 
pre-treatment, with the optimal duration approaching 
24 hours.6 Following PCI, long-term clopidogrel treatment 
(1 year) was associated with a 26.9% relative reduction in the 
combined risks of death, MI, or stroke (P = 0.02).
The beneficial effect of increasing clopidogrel load-
ing dose to 600 mg in achieving a more rapid and intense 
platelet suppression and ameliorating outcomes has not been 
consistently demonstrated. Results of the ARMYDA-2 study 
demonstrated that pretreatment with a 600 mg loading dose 
of clopidogrel 4–8 hours before PCI (n = 126) significantly 
reduced periprocedural adverse cardiac events compared 
with the conventional 300 mg dose (n = 129). The primary 
end point of death, MI, or target vessel revascularization at 
30 days occurred in 4% and 12% of patients in the high- vs 
conventional-loading dose groups, respectively (P = 0.041). 
Multivariate analysis demonstrated that the 600 mg loading 
dose was associated with a 50% reduction in the risk of 
periprocedural MI (OR 0.48, P = 0.044).7 Safety data were 
comparable between the two treatment groups. However, the 
methodological aspects of the ARMYDA-2 trial have been 
challenged by experts in the field because only a per-protocol 
analysis (only patients who underwent PCI were included) 
rather than an intention-to-treat analysis was performed.8 
Furthermore, the study sample consisted of a small number 
of patients (n = 255) and only moderate-risk patients were 
enrolled in the study.
In contrast to the ARMYDA-2 study, a retrospective study 
of 445 patients with stable angina who underwent PCI failed 
to demonstrate a beneficial effect of a high- vs conventional-
loading dose in reducing 30-day major adverse cardiac events. 
Major bleeding was also similar between the two treatment 
groups. The authors concluded that although 600 mg was 
clinically safe, it was not associated with fewer periprocedural 
events or improved 30-day outcomes compared to 300 mg 
loading dose.9 Nevertheless, it should be noted that in this 
study clopidogrel loading dose was administered immedi-
ately before the procedure, which might be inadequate for 
providing protective antiplatelet aggregation in either treat-
ment group.
In a meta-analysis of 10 studies (7 randomized, 3 non-
randomized) consisting of over 1,500 patients (712 loaded 
with 300 mg, 11 with 450 mg, 790 with 600 mg, and 54 with 
900 mg), Lotrionte et al10 demonstrated that a high loading 
dose was significantly superior to a standard loading dose 
in preventing cardiac death or nonfatal MI (odds ratio 0.54, 
95% CI 0.32 to 0.90, P = 0.02) without increasing the risk of 
major or minor bleeding (P = 0.55 and P = 0.98, respectively). 
Notably, meta-regression analysis suggested that the greatest 
benefits of a high loading dose were seen in the highest risk 
participants. Although most systematic reviews have some 
inherent limitations and the results may not be applicable to 
various patient populations, the authors concluded that the 
robustness of the study was supported by the magnitude of 
statistical significance, even in sensitivity analysis restricted 
to randomized trials.
In concert with the ARMYDA-2 study, results gained 
in the CURRENT-OASIS 7 study showed reduced com-
posite end points of cardiovascular death, MI, and stroke 
as well as reduced stent thrombosis through 30 days with 
high-dose clopidogrel (600 mg loading followed by 150 mg 
for one week) therapy in ACS patients undergoing PCI. 
The reduction reached statistical significance but with an 
increased CURRENT major and severe bleeding. There was 
no significant difference in TIMI major, intracranial hemor-
rhage, or CABG-related bleeding.
The ISAR-REACT study investigators were among the 
first to demonstrate that the duration of high-dose clopidogrel 
pretreatment beyond 2 hours conferred no additional benefits 
among low- to intermediate-risk patients undergoing PCI.11 Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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In this study over 2,000 patients with CAD who underwent 
PCI were randomized to receive adjunctive therapy with 
either abciximab or placebo. All patients were treated with 
600 mg oral loading dose of clopidogrel at least 2 hours 
before elective PCI. Subgroup analysis of patients based on 
the duration of clopidogrel pretreatment (2 to 3 h, 3 to 6 h, 
6 to 12 h, or .12 h) showed no significant differences in the 
30-day composite end points of death, MI, or urgent revas-
cularization or its individual components between patient 
groups irrespective of assignment to abciximab or placebo 
(P = 0.79 across groups). In the ISAR-CHOICE study, the 
same group of investigators demonstrated that a single dose 
of clopidogrel higher than 600 mg was not associated with 
additional suppression of platelet function (P = NS).12 In their 
single-center study, 60 patients with suspected or documented 
CAD were randomly assigned to one of the three clopidogrel 
loading dose (300, 600, or 900 mg). Pharmacokinetic studies 
demonstrated that increasing clopidogrel loading dose from 
600 mg to 900 mg resulted in no further increase in plasma 
concentrations of the active metabolite and the unchanged 
form of the drug (P . 0.38) and no further suppression of 
ADP-induced platelet aggregation compared with the 600 mg 
clopidogrel dose. It is speculated that the lack of further 
beneficial response with doses higher than 600 mg may be 
due to limited intestinal absorption.12
Clopidogrel trials and outcomes are summarized in 
Table 2.
Prasugrel
Prasugrel is a potent third generation thienopyridine with a 
more rapid onset of action than clopidogrel. Studies involv-
ing healthy participants suggest that orally administered 
prasugrel provides faster, higher, and more consistent inhi-
bition of platelet aggregation compared to clopidogrel.13 
Phase III clinical trials involving moderate- to high-risk 
patients with ACS undergoing PCI have demonstrated that 
prasugrel was superior to clopidogrel in reducing major 
adverse cardiac events albeit with increased risk of TIMI 
major hemorrhage.
TRITON-TIMI 38 was the first large-scale clinical events 
trial in which it was assessed whether the higher level of inhi-
bition of platelet aggregation achieved by prasugrel resulted 
in an improvement in clinical outcomes compared with stan-
dard clopidogrel pretreatment. In this study, 13,608 patients 
with moderate- to high-risk ACS (10,074 with unstable 
angina/NSTEMI and 3,534 with STEMI) and with scheduled 
PCI were randomly assigned to receive prasugrel (60 mg 
loading dose followed by 10 mg daily   maintenance dose) or 
clopidogrel (300 mg loading dose   followed by 75 mg daily 
maintenance dose for 6 to 15 months).14 The primary efficacy 
end point (death from cardiovascular causes, nonfatal MI, or 
nonfatal stroke) occurred in 9.9% and 12.1% of   prasugrel- vs 
clopidogrel-treated patients (HR 0.81, P , 0.001). Prasugrel-
treated patients also showed a significant reduction in the 
incidence of MI (7.4% vs 9.7%, respectively, P , 0.001), 
urgent target-vessel revascularization (2.5% vs 3.7%, respec-
tively, P , 0.001), and stent thrombosis (1.1% vs 2.4%, 
respectively, P , 0.001). However, major bleeding occurred 
in 2.4% of patients receiving prasugrel compared to 1.8% 
of those receiving clopidogrel (HR, 1.32, P = 0.03). Life-
threatening bleeding including nonfatal and fatal bleeding 
was also significantly higher in the prasugrel-treated groups. 
However, there were no significant differences between 
treatment groups in the overall   mortality rate (ie, cardio-
vascular death or death from any cause). Post hoc analysis 
demonstrated that patients with a history of stroke or transient 
ischemic attack (TIA) had a net harmful effect from prasugrel 
whereas those older than 75 years of age, and those weigh-
ing less than 60 kg had no net clinical benefit from prasugrel 
treatment. It should also be noted that in this study nearly 
75% of patients received the study drug during PCI whereas 
only 25% to 26% of patients in each arm received study drug 
before PCI, which might not be relevant to current practice 
guidelines.
In an analysis involving STEMI patients in the TRITON-
TIMI 38 study (n = 3,534), Montalescot et al15 demonstrated 
that prasugrel was associated with a significant reduction in 
the primary composite end points of cardiovascular death, 
non-fatal MI, or non-fatal stroke at 30 days and 15 months 
follow-up and there was no significant increase in major 
bleeding risk between the treatment groups during the 
study period. However, TIMI major bleeding after coronary 
artery bypass graft surgery was significantly increased in 
  prasugrel- compared to clopidogrel-treated groups (OR 8.19, 
P = 0.0033).
In summary, the TRITON-TIMI 38 demonstrated that 
prasugrel therapy was associated with significantly reduced 
rates of ischemic events including stent thrombosis, but with 
an increased risk of major bleeding in a subset of patients. 
The drug was approved by the US Food and Drug Admin-
istration (FDA) in July 2009 for use in patients with ACS 
undergoing PCI. The clinical use of prasugrel will most 
likely be in the setting of STEMI. There are no clinical   trials 
as of yet   supporting the safety of “upstream” prasugrel use 
in the setting of NSTEMI. Patients with NSTEMI in the 
TRITON-TIMI 38 trial were not randomized until after Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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definition of the coronary anatomy was made by coronary 
angiography. Prasugrel is not yet recommended for routine 
use in elective PCI unless patients are felt to be at higher risk 
of thrombosis by their interventional cardiologists. Prasugrel 
is contraindicated in patients with a prior history of stroke 
or TIA. The package insert recommends decreasing the daily 
maintenance dosage from 10 mg to 5 mg in patients weigh-
ing less than 60 kg although there is no clinical evidence 
supporting its safety.
The TRILOGY ACS is an ongoing trial comparing the 
relative efficacy and safety of prasugrel and clopidogrel in 
medically treated unstable angina/NSTEMI ACS patients. This 
trial has an expected completion date of October 2011.16
Thienopyridines current status
Currently available data support the use of high-dose clopi-
dogrel loading (600 mg) if given . 2–6 hours pre-PCI, and 
standard-dose (300 mg) if given . 6–12 hours pre-PCI. 
Pharmacokinetic study results suggest that clopidogrel 
  loading doses higher than 600 mg offer no additional ben-
eficial effects on platelet function suppression due to limited 
  clopidogrel absorption. However, large randomized trials 
evaluating clinical end points are needed. Clopidogrel 75 mg 
daily should be continued for a variable period depending 
in part on stent type (eg, one month for bare metal stent, 
one year with drug eluting stent except in patients at high risk 
for bleeding – or three months for Cypher, and six months for 
Taxus stent). For patients with ACS, clopidogrel should be 
continued for at least one year regardless of stent type.
In STEMI patients undergoing primary PCI, the ACC/
AHA guidelines recommend administration of clopidogrel 
300 mg or 600 mg, favoring the 600 mg dose, or prasugrel 
60 mg as soon as possible (Class I; Level of Evidence C for 
clopidogrel and B for prasugrel). If stents are implanted, BMS 
or DES, clopidogrel 75 mg daily or prasugrel 10 mg daily 
should be continued for at least 12 months unless the risk of 
Table 2 Clopidogrel trials and outcomes
Trial Study drug N 10 endpoints Outcomes/comments
PCi-CURe 300 mg Clopidogrel loading 
(Clopidogrel given median  
10 days before PCI) 
Placebo
1,313 
 
 
1,345
Composite endpoints of Cv  
death, Mi, or urgent revascularization  
by 30 days after PCi
Compared with placebo,  
clopidogrel ↓ the risks of  
composite endpoints by nearly  
1/3 (RR = 0.70, P = 0.03)
CReDO 300 mg Clopidogrel loading
Placebo
1,053
1,063
Combined risks of death, Mi or urgent
revascularization @ day 28
No difference between the
2 treatment groups
Post-hoc: Clopidogrel better  
if given .15 hrs before PCi
ARMYDA-2 600 mg clopidogrel loading 126 Combined risks of death, Mi, or target 600 mg versus 300 mg, no
300 mg clopidogrel loading 129 vessel revascularization @ 30 days difference (P = 0.041)
Multivariate analysis:  
50% ↓ peri-procedure Mi  
with 600 mg clopidogrel 
Comparable safety
CURReNT-OASiS 7* Clopidogrel analysis:  
600 mg loading, followed  
by 150 mg × 7 days, then  
75 mg daily 300 mg loading, 
followed by 75 mg daily
12,508  
12,579
Composite endpoints of  
Cv death, Mi, or stroke  
@ 30 days
600 mg versus 300 mg, no  
difference (P = 0.37)  
PCi subgroup:  
↓ Composite endpoints  
(HR 0.85, P = 0.036) and  
↓ Definite stent thrombosis with 
high dose (P = 0.001)  
↓ Current major and severe 
bleeding with high dose (P = 0.01)
iSAR-ReACT Duration of 600 mg  
clopidogrel treatment before 
 PCi with or without abciximab  
(2–3 h, 3–6 h, 6–12 h, or .12 h)
2,159 Composite endpoints of death, Mi, or  
urgent revascularization @ 30 days
No incremental benefit with  
clopidogrel pretreatment 
.2–3 h (P = 0.79) with or  
without abciximab
iSAR-CHOiCe Clopidogrel 300 mg, 600 mg,  
or 900 mg loading
60 Plasma concentrations of active  
and inactive clopidogrel metabolites,  
and unchanged clopidogrel; values  
for ADP-induced platelet aggregation  
4 h after clopidogrel
600 mg versus 900 mg  
No further increase in  
concentrations of metabolites  
(P = 0.59) or ADP-induced  
platelet aggregation (P = 0.39)
*within each clopidogrel group (600 mg versus 300 mg loading), patients were randomized to receive high-dose or low-dose aspirin (300–325 mg or 75–100 mg).
Abbreviation: N, number of patients.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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bleeding outweighs the benefit (Class I). Prasugrel should 
not be given as part of the dual antiplatelet therapy in patients 
with a prior history of TIA or stroke (Class III).
Selected UA and NSTEMI patients undergoing invasive 
therapy should also receive dual antiplatelet therapy includ-
ing aspirin with clopidogrel before or at the time of PCI or 
prasugrel at the time of PCI (Class I; Level of Evidence A 
for clopidogrel and B for prasugrel).17
Nonthienopyridines
Ticagrelor
Ticagrelor is the first reversible oral P2Y12 receptor antagonist 
of the nonthienopyridine class. It has a rapid onset of action 
and a half-life of approximately 12 hours. Phase II trial con-
ducted in stable atherosclerosis patients demonstrated a dose-
dependent increase in the level of inhibition with ticagrelor, 
with levels significantly higher than those achieved with 
clopidrogel.18 Similarly, in the phase-2   DISPERSE trial 
involving NSTEMI patients who were randomized to receive 
either ticagrelor 90 or 180 mg twice daily, or clopidrogel 
300-mg loading dose, ticagrelor has been shown to exhibit 
greater mean inhibition of   platelet aggregation than a stan-
dard regimen of clopidogrel.19 Safety data profile showed an 
increase in minor bleeding at the higher dose but no differ-
ence in major bleeding was observed. The rates of MI were 
lower in the ticagrelor compared to the clopidrogel groups, 
although this did not reach statistical significance.19
The phase III PLATO trial was a multicenter, double-blind, 
randomized trial comparing ticagrelor (180 mg loading dose, 
90 mg twice daily thereafter) with clopidogrel (300 mg to 
600 mg loading dose, 75 mg daily thereafter) for the   prevention 
of cardiovascular events in over 18,000 patients admitted with 
ACS, with or without ST-segment   elevation.20 At 12 months 
follow-up, ticagrelor as compared with clopidogrel signifi-
cantly reduced the primary composite end point of death from 
vascular causes, MI, or stroke (9.8% vs 11.7% in the ticagre-
lor vs clopidrogel group, respectively, P , 0.001) without 
an increase in the rate of overall major bleeding but with an 
increase in the rate of non-procedural related bleeding and a 
trend towards more hemorrhagic strokes in the   ticagrelor- vs 
the clopidogrel-group (0.2% vs 0.1% respectively; P = 0.10). 
Other ticagrelor-related adverse events include dypsnea, 
ventricular pauses, and slightly increased creatinine and uric 
acid levels. Notably, discontinuation of the study drug due 
to adverse events occurred in 7.4% of   ticagrelor- vs 6.0% of 
clopidrogel-treated patients (P , 0.01).
The advantages of ticagrelor vs clopidogrel were seen 
in ACS patients with or without ST-segment elevation, in 
patients undergoing invasive or non-invasive treatment, and 
in patients who had or had not received the currently recom-
mended pretreatment of higher loading dose of clopidogrel. 
The only exception was the attenuated benefit of ticagrelor in 
patients weighing less than the median weight for their gender 
in the study, in patients not taking lipid-lowering drugs at 
randomization, and in patients enrolled in North America. 
Ticagrelor has not been approved by the FDA in the US.
Cangrelor
Similar to ticagrelor, cangrelor is a nonthienopyridine that 
binds reversibly to the platelet P2Y12 receptor. It has a rapid 
onset of action (within seconds if a bolus dose is adminis-
tered), a rapid offset, and a half-life of a few minutes with 
complete recovery of platelet function within 1 hour.21 The 
CHAMPION PLATFORM trial was a double-blind, placebo-
controlled study randomizing over 5000 patients into the 
cangrelor or placebo group at the time of PCI, followed by 
administration of 600 mg clopidogrel.22 Enrollment was 
stopped prematurely because an interim analysis failed to 
demonstrate the superiority of cangrelor over placebo in 
reducing the primary composite end points of death, MI, or 
ischemia-driven revascularization at 48 hours (P = 0.17). 
The pre-specified secondary end points, rate of stent throm-
bosis, and rate of death from any cause at 48 hours, were 
significantly reduced in the cangrelor group but should be 
interpreted with caution in the absence of a positive primary 
end point finding. In addition, the rate of major bleeding in the 
study group was higher mainly due to more groin hematomas 
based on the GUSTO bleeding scale.
The CHAMPION PCI trial compared cangrelor with 
600 mg of clopidogrel administered before PCI in nearly 
9,000 patients with ACS.23 The primary efficacy end point, 
a composite of death from any cause, MI, or ischemia-
driven revascularization at 48 hours occurred in 7.5% of the 
cangrelor group and 7.1% of the clopidogrel group (odds 
ratio 1.05; 95% CI 0.88–1.24; P = 0.59). Cangrelor was also 
not superior to clopidogrel at 30 days. The secondary end 
points of death from any cause, Q-wave MI, or ischemia-
driven revascularization showed a reduction trend favoring 
cangrelor but were not statistically significant. As seen in 
the CHAMPION PLATFORM trial, there was also a trend 
towards more major bleeding in the cangrelor group based 
on the GUSTO bleeding scale.
Despite the negative primary efficacy end points and 
safety concerns with cangrelor from both CHAMPION trials, 
cangrelor may be an attractive drug for “bridging therapy” 
in the perioperative setting due to its rapid onset and offset Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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of action, and its reversibility. The BRIDGE study is an 
  ongoing study designed to demonstrate that patients receiv-
ing cangrelor infusion before coronary artery bypass grafting 
have an acceptable safety profile and can undergo surgery 
without excessive bleeding perioperatively. This study has 
an expected completion date of July 2010.24
Glycoprotein IIB/IIIA inhibitors
Inhibition of glycoprotein IIb/IIIa receptors – the final com-
mon pathway of platelet-thrombus formation (Figure 1) – has 
been shown to reduce thrombotic complications associated 
with PCI.
Results gained in early studies demonstrated no clinical 
benefit from routine early invasive management compared 
with conservative ischemia-guided management in patients 
with NSTEMI (eg, the TIMI IIIB trial, the VANQWISH 
trial, and the MATE trial).28 However, with the advent of 
coronary stents and glycoprotein IIb/IIIa inhibitors, inde-
pendent investigators have sought to evaluate the short- and 
long-term outcomes of a routine invasive strategy compared 
with a selective strategy in patients with UA and NSTEMI 
in the pre- compared with the post-glycoprotein IIb/IIIa and 
coronary stenting era. The TIMI IIIB and the TACTICS-
TIMI 18 were both trials of an early invasive strategy in 
patients with UA/NSTEMI with nearly identical study 
design and patient enrollment criteria.25,29 However, the 
two studies were conducted 10 years apart, and the use of 
upstream GP IIb/IIIa was mandated and coronary stenting 
was routinely used in TACTICS-TIMI 18. Among patients 
matched for similar degrees of baseline risks, patients in 
TACTICS-TIMI 18 had significantly lower rates of the 
composite end points of death, MI, or rehospitalization 
for ACS through 6 months compared with patients in 
TIMI IIIB, after adjusting for differences in baseline risk. 
Although the favorable outcomes in the TACTICS-TIMI 18 
compared with the TIMI IIIB trials were likely multifacto-
rial, including advances in the care of patients with UA/
NSTEMI, GP IIb/IIIa inhibition, and coronary stenting, the 
investigators speculated that the differences in outcomes 
most likely reflect the use of GP IIb/IIIa inhibitors and 
coronary stenting in TACTICS-TIMI 18.
Similar to the TACTICS-TIMI 18 trial, analysis of the 
CRUSADE community-based registry database consisting 
of over 55,000 NSTE MI patients demonstrated a beneficial 
effect of early GP IIb/IIIa inhibition in reducing the risk of 
in-hospital mortality in patients at all risk levels. Notably, 
among troponin-positive patients, GP IIb/IIIa inhibition was 
associated with an even lower adjusted mortality risk.30
Activated
platelet
G
P Fibrinogen
Fibrinogen
GP IIb/IIIa inhibitors
Abciximab
Eptifibatide
Tirofiban
Figure 1 Site of action of glycoprotein iib/iiia inhibitors.
Aggregation requires activated platelets, glycoprotein receptor IIb/IIIa (GP), and fibrinogen. The latter acts as a bridge that attaches platelet to each other forming the initial 
hemostatic plug. The current ACC/AHA guidelines recommend the use of GP iib/iiia antagonists in high-risk patients with STeMi-ACS and planned percutaneous coronary 
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Currently available GP IIb/IIIa inhibitors include 
  abciximab, tirofiban, and eptifibatide. Selected trials involv-
ing the use of each individual GP IIb/IIIa inhibitor in patients 
undergoing PCI are discussed.
Abciximab
Abciximab is a chimeric monoclonal antibody with a high 
affinity receptor binding and a long biological half-life. Unlike 
eptifibatide or tirofiban which are selective for the GP IIb/IIIa 
receptor, abciximab receptor binding is   nonspecific. In the 
early EPIC trial consisting of patients at high risk for throm-
botic complications after coronary intervention, abciximab 
has been shown to reduce ischemic complications of coro-
nary intervention albeit with an increased risk of bleeding.31 
Subsequent large randomized controlled trials extend the 
findings of the EPIC trial on the beneficial role of GP IIb/IIIa 
inhibitors in patients undergoing PCI.
In a European meta-analysis of three randomized trials 
(ISAR-2, ADMIRAL, and ACE) in which patients under-
going primary PCI and stenting for ST-elevation MI were 
  randomized to receive abciximab (n = 550) or placebo 
(n = 551), Montalescot et al32 demonstrated a 37% relative 
risk reduction in death or reinfarction in abciximab- compared 
to placebo-treated groups (RR 0.633, P = 0.008). Similarly, 
mortality rates were reduced in the abciximab- compared to 
placebo-treated arms although this did not reach statistical 
significance (P = 0.05). The impact of abciximab on the 
primary outcomes was observed up to 3 years of follow-up. 
Major bleeding occurred in 2.5% and 2.0% of abciximab 
and placebo-treated groups, respectively (P = NS). Notably, 
there was a 47.5% relative risk reduction in the primary 
endpoint of death or MI, and an 85% relative risk reduction 
in reinfarction in diabetics compared to their non-diabetic 
counterparts (P = 0.022).
Eptifibatide
Eptifibatide is a small cyclic heptapeptide that is highly 
specific for the GP IIb/IIIa receptor. It has a relatively low 
binding affinity and rapidly dissociates from its receptor 
after cessation of therapy, leading to an early restoration of 
platelet function after discontinuation of infusion. Its time to 
restoration of normal platelet aggregation after cessation of 
therapy is 4 hours, compared to 72 hours for abciximab.
In the IMPACT-II trial consisting of 4,010 patients 
undergoing elective, urgent, or emergency PCI who were 
randomized to receive placebo or bolus eptifibatide followed 
by two different dosing regimen of continuous infusion 
therapy (135 µg/kg eptifibatide followed by an infusion of 
0.5 µg/kg/min for 20–24 h or 0.75 µg/kg/min infusion), a 
significant reduction in the primary composite end points of 
death, MI, or urgent target vessel revascularization at 30 days 
was demonstrated in the 135/0.5 treated-group (11.6% vs 
9.1%, eptifibatide vs placebo, respectively, P = 0.035), with 
a less substantial reduction in the 135/0.75 treated- group 
(11.6% vs 10.0%, eptifibatide vs placebo, respectively, 
P = 0.18). There was no significant increase in the primary 
safety end point of major bleeding in eptifibatide-treated 
groups.33
In a subsequent randomized, double-blind, placebo-
controlled, crossover-permitted ESPRIT trial (n = 2,064) 
using double-bolus eptifibatide therapy followed by infusion 
therapy at a dose that was 4-fold higher than that used in 
the IMPACT-II study, O’Shea et al34 demonstrated that in 
patients undergoing non-urgent PCI with stent implantation, 
eptifibatide significantly reduced the primary composite end 
points of death, MI, and urgent target vessel revasculariza-
tion within 48 h compared with placebo (0.3% vs 0.4%, 
P = 0.027). The beneficial effect of adjunctive eptifibatide 
therapy was maintained through six months of follow up.
Tirofiban
Tirofiban is a small nonpeptide tyrosine derivative GP IIb/IIIa 
antagonist. Similar to eptifibatide, tirofiban is a selective 
inhibitor of the GP IIb/IIIa receptor with a rapid onset of 
action and a short half-life of 2–4 hours. Its action is rapidly 
reversible upon cessation of therapy. Such reversibility may 
have important clinical implications such as in the setting of 
emergent coronary artery bypass graft surgery when rapid 
reversal of antithrombotic effects is desirable.
Early studies in which lower-dose bolus tirofiban was used 
failed to demonstrate the non-inferiority of tirofiban as com-
pared with abciximab in patients undergoing percutaneous 
coronary revascularization with the intent to perform stenting 
of a newly stenotic or restenotic atherosclerotic lesions of a 
native vessel or bypass graft.35 However, subsequent trials 
using high-dose bolus tirofiban support its efficacy in patients 
with STEMI undergoing PCI. The ON-TIME 2 trial was the 
first randomized, placebo-controlled trial evaluating whether 
pre-hospital initiation of high-bolus dose tirofiban in addition 
to dual antiplatelet therapy improved ST-segment resolution 
and clinical outcome after PCI.36 A total of 984 patients with 
STEMI who were candidates to undergo PCI were randomly 
assigned to either high-bolus dose tirofiban (n = 491) or 
placebo (n = 493) in addition to aspirin (500 mg), heparin Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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(5000 IU), and clopidogrel (600 mg). The study drug was 
initiated at a median of 76 minutes after symptom onset 
and 55 minutes prior to angiography/PCI. The cumulative 
residual ST-segment deviation was significantly lower in 
the tirofiban compared to placebo groups 1 hour post-PCI 
(3.6 mm [SD 4.6] vs 4.8 mm [SD 6.3], P = 0.003). There 
was no significant increase in the rates of major bleeding 
between the two groups (4% vs 3%; P = 0.36). At 30 days 
there was a significant reduction in the combined incidence 
of death, recurrent MI, urgent target vessel revascularization, 
or thrombotic bailout in the tirofiban compared to placebo 
groups (26% vs placebo 32.9%, P = 0.02). Further analy-
sis suggested an association between the level of residual 
ST-segment deviation and mortality.
Similarly, the MULTISTRATEGY trial involving 
745 patients presenting with STEMI or new left bundle-
branch block demonstrated that high-dose bolus regimen 
of tirofiban was superior to standard dose abciximab in 
ST-segment recovery at 90 minutes following coronary 
intervention.37 With regard to stent type, sirolimus-eluting 
stent implantation was associated with a significantly 
lower risk of major adverse cardiac events compared to 
uncoated stents within eight months after intervention 
owing primarily to a reduction of revascularization rates 
(10.2% vs 3.2%). The incidence of ischemic and hemor-
rhagic outcomes was similar between the tirofiban and 
abciximab groups.
Abciximab, eptifibatide, and tirofiban  
in the setting of PCi: meta-analysis
In a meta-analyis of 21 randomized trials comparing 
GP IIb/IIIa inhibitors with controls (in which 15 used 
  abciximab, four used eptifibatide, and two used tirofiban), 
Labinaz et al38 demonstrated that treatment with GP IIb/IIIa 
in the setting of PCI significantly reduced 30-day mortality 
rates, MI, and revascularization procedures. At 30 days there 
was a significant 0.38% absolute reduction in the primary 
outcome of all-cause mortality. The reduction in mortality 
rate was seen as early as 7 days but the benefit appeared to 
dissipate by six months and was of borderline significance 
at one year. Similarly, the beneficial effect of GP IIb/IIIa 
inhibitors in reducing both MI and the need for repeat 
revascularization was observed as early as seven days and 
persisted to 30 days and six months. The early reduction in 
clinical events associated with GP IIb/IIIa inhibition was 
thought to be consistent with the pharmacodynamic effects 
of these agents whereby potent GP IIb/IIIa antagonism 
reduces local platelet deposition at the site of PCI. This 
results in a reduction in the local platelet-mediated vasocon-
striction, distal vessel platelet-thrombin microembolization 
and abrupt vessel closure – all of which may contribute to 
the   reduction in reinfarction risk and the subsequent need 
for repeat   revascularization procedures.38 The beneficial 
effects of GP IIb/IIIa inhibitors are achieved at an increased 
risk of thrombocytopenia (OR 1.41, 95% CI 1.10 to 1.81) 
and minor bleeding (OR 1.80, 95% CI 1.47 to 2.21), but not 
major bleeding (OR 1.29, 95% CI 0.98 to 1.68).
GP IIb/IIIa trials and outcomes are summarized in 
Table 3.
GP iib/iiia inhibitors current status
In selected STEMI patients, the ACC/AHA guidelines 
recommend treatment with a GP IIb/IIIa receptor antago-
nist at the time of primary PCI with or without stenting 
(Class IIa; Level of Evidence A for abciximab and B for 
eptifibatide and tirofiban). The usefulness of these agents 
as routine treatment in STEMI patients is uncertain (Class 
IIb) but its beneficial effect may be greater in the presence 
of inadequate thienopyridine loading or large thrombus 
burden.
Patients with UA or NSTEMI undergoing early invasive 
treatment may be administered GP IIb/IIIa receptor antagonist 
or clopidogrel before angiography (Class I; LOE A). In the 
setting of recurrent ischemia or high risk features includ-
ing positive troponin, both GP IIb/IIIa receptor antagonist 
and clopidogrel may be given in addition to aspirin before 
angiography (Class IIa; LOE B). Abciximab should not be 
administered if PCI is delayed for over 24 hours (Class III).
Antithrombins
indirect thrombin inhibitors
Unfractionated heparin
The heparins, Unfractionated heparin (UFH) are indirect 
thrombin inhibitors that complex with antithrombin (AT) 
and convert AT from a slow to a rapid inactivator of throm-
bin, factor Xa, and to a lesser extent, factors XIIa, XIa, and 
IXa. UFH has been the standard adjunctive antithrombin 
therapy during PCI for nearly three decades. However, there 
are several intrinsic limitations to heparin therapy including 
its inability to bind clot-bound thrombin. More importantly, 
such clot-bound thrombin remains enzymatically active, 
amplifying its own generation leading to further thrombus 
formation. Other disadvantages of UFH include its depen-
dence on AT for inhibition of thrombin activity, sensitivity 
to platelet factor 4, and marked interindividual variability in 
therapeutic response. To overcome some of the limitations Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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of the heparins, newer agents with more predictable pharma-
cokinetics and anticoagulant effect are being evaluated for 
their safety and efficacy in the setting of PCI. These include 
enoxaparin, fondaparinux, and bivalirudin.
enoxaparin
Enoxaparin is a low molecular weight heparin with a longer 
half-life and greater anti-Xa activity than UFH, and less plasma 
and protein binding. It has a high bioavailability with signifi-
cantly less interindividual variation in therapeutic response 
than UFH. In patients with normal renal function the drug 
can be given subcutaneously without the need for laboratory 
monitoring or dose adjustment. Enoxaparin has been shown 
to be superior to UFH in reducing ischemic events in patients 
treated conservatively for NSTEMI. However, studies of high-
risk patients undergoing early coronary intervention failed 
to demonstrate the superior effectiveness of enoxaparin over 
UFH. In the SYNERGY trial involving 4,687 high-risk patients 
with non-ST-segment elevation ACS undergoing PCI who were 
randomized to receive enoxaparin or UFH, White et al39 dem-
onstrated similar rates of death and MI at 30 days between the 
two treatment groups (enoxaparin vs UFH: 13/1% vs 14.2%, 
respectively, P = 0.289). The incidence of GUSTO severe 
bleeding was comparable between the two treatment groups 
(P = 0.289) whereas TIMI major bleeding was significantly 
higher in the enoxaparin group (enoxaparin vs UFH: 3.7% vs 
2.5%, respectively, P = 0.28). The authors concluded that in 
high-risk patients undergoing PCI for ACS, enoxaparin avoids 
the need for monitoring and achieves similar effectiveness to 
UFH but is   associated with more bleeding. The routine recom-
mendation of enoxaparin use in high-risk patients undergoing 
PCI awaits further study.
Table 3 Glycoprotein iib/iiia trials and outcomes
Trial Study drug N 10 endpoints Outcomes/comments
european
Meta-analysis
(iSAR-2, ACe,  
ADMiRAL)
Abciximab
Placebo
550
551
Composite of death  
or re-infarction;
up to 3 years of  
follow-up
Compared with placebo, 
abciximab ↓ the composite 
endpoints by 37%  
(RR = 0.633, P = 0.008)
Diabetics versus non-
diabetics: ↓ composite 
endpoints and re-infarction 
(P = 0.022)
No difference in major 
bleeding
iMPACT-ii Eptifibatide bolus followed  
by two continous infusions  
(Bolus 135 ug/kg, infusion 
0.5 or 0.75 ug/kg/min ×  
20–24 h)  
Placebo
4,010 (total)
1,349 (infusion @ 50)
1,333 (infusion @ 75)
1,328 (placebo)
Composite of death,  
Mi, or urgent target vessel  
revascularization @ 30 days
Eptifibatide 135/0.5 versus 
placebo 11.6% versus 9.1%, 
respectively (P = 0.035)
Eptifibatide 135/0.75  
versus placebo  
11.6% versus 10.0%, 
respectively (P = NS)
No difference in major 
bleeding in eptifibatide-
treated groups
eSPRiT
 
 
 
ON-TiMe 2
Double-bolus eptifibatide  
followed by high-  
dose infusion  
Placebo
Pre-hospital high-bolus  
dose tirofiban + DAT + 
heparin
Placebo + DAT + heparin
1,040 (eptifibatide)
1,024 (placebo)
 
 
491
493
Composite of death, Mi,  
or urgent target vessel  
revascularization through  
6 months
Combined incidence  
of death, recurrent Mi,  
urgent target vessel 
revascularization,
or thrombotic bailout @  
30 days; ST- segment  
resolution
Eptifibatide versus placebo 
(0.3% versus 0.4%,  
P = 0.027)
 
Tirofiban versus placebo  
26% versus 32.9%, 
respectively
(P = 0.02) in STeMi  
with PCi
Lower residual ST-segment 
deviation 1 h after PCi 
(P = 0.003)
No difference in rates of 
major bleeding between 
groups
Abbreviation: N, number of patients.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
214
Pham et al
The ATOLL trial is an ongoing randomized trial evaluating 
enoxaparin vs unfractionated heparin in lowering ischemic 
and bleeding events in patients with acute STEMI treated with 
primary angioplasty. The trial has an expected completion 
date of January 2012.40
Fondaparinux
Fondaparinux is an indirect synthetic factor Xa inhibitor 
that binds to AT with a higher affinity than UFH or LMWH, 
and causes a conformational change in AT that significantly 
increases the ability of AT to inactivate factor Xa. The 
binding of fondaparinux to AT causes rapid and predictable 
inhibition of factor Xa. It has a half-life of 15 hours, with 
linear pharmacokinetics and low inter- and intra-individual 
variability obviating the need for laboratory monitoring. 
However, it should be noted that unlike heparin, fondaparinux 
is not inactivated by protamine and currently has no known 
antidote.
In a pilot, phase II, randomized, multicenter, blinded 
ASPIRE trial comparing two dosing regimen of fonda-
parinux with UFH in patients undergoing PCI, Mehta et al41 
demonstrated similar bleeding complications and composite 
efficacy outcome of all-cause mortality, myocardial   infarction, 
urgent revascularization, or need for a bailout GP IIb/IIIa 
antagonist between UFH and the combined fondaparinux 
groups. Bleeding was less common in the 2.5 mg- com-
pared to the 5 mg-fondaparinux group although this did 
not reach statistical significance (P = 0.06). In a subse-
quent OASIS-6 trial involving 3,788 patients with STEMI 
undergoing primary PCI who were randomized to receive 
UFH for 4–48 hours vs fondaparinux 2.5 mg SQ daily for 
up to 8 days in a placebo-controlled double-blind trial, the 
30-day composite end points of death or reinfarction and 
bleeding complications were comparable between UFH and 
  fondaparinux groups (P = NS).42 However, there were higher 
rates of coronary complications in the fondaparinux-treated 
groups largely due to guiding catheter thrombosis. It should 
be noted that in patients undergoing primary PCI, intrave-
nous heparin was used in all patients in the control group 
(by protocol design) whereas only 21% in the fondaparinux 
group received   heparin. Further analysis demonstrated that 
among 496 patients who received UFH prior to primary 
PCI, the rates of clinical complications (coronary complica-
tions, catheter thrombus, and severe bleeding) were similar 
between fondaparinux and control groups. The results of 
both OASIS-5 (comparing fondaparinux vs enoxaparin in 
ACS)43 and OASIS-6 trials suggest that using UFH with 
fondaparinux during PCI substantially reduces the risk of 
catheter thrombosis and related complications without an 
increase in clinical complications or major bleeds. None-
theless, currently available data do not support a role for 
fondaparinux during PCI for stable or unstable coronary 
artery disease.
Indirect thrombin inhibitor trials and outcomes are sum-
marized in Table 4.
Direct thrombin inhibitors
Bivalirudin
Bivalirudin is a bivalent synthetic, reversible direct thrombin 
inhibitor that overcomes several limitations of heparin includ-
ing its ability to inhibit clot-bound thrombin. Unlike heparin, 
bivalirudin does not require cofactors and is not neutral-
ized by platelet product. In addition, it has a short half-life 
(25 minutes) that allows for a rapid return to hemostasis. 
Table 5 summarizes the advantages of bivalirudin over 
heparin.
Early clinical trials conducted for patients with unstable 
angina during PCI have shown that bivalirudin reduces 
Table 4 indirect thrombin inhibitor trials and outcomes
Trial Study drug N 10 endpoints Outcomes/comments
SYNeRGY enoxaparin
UFH
2,323
2,364
Composite of death  
and Mi @ 30 days
No difference between 2 groups
Trend towards ↑ TiMi major bleeding with enoxaparin 
(P = 0.28)
No difference in GUSTO severe bleeding between 2 groups
OASiS-6 Fondaparinux 2.5 mg  
UFH for 4–48 h
3,788 (total)*
1,890 (Fondaparinux)
1,898 (UFH)
Composite of death  
or reinfarction
No difference in composite endpoints between 2 groups
No difference in bleeding complications
increased catheter thrombosis with fondaparinux (P , 0.001)
Of the 21% in the fondaparinux group receiving UFH before  
10 PCi, rates of coronary complications, catheter thrombosis, 
and severe bleeding were similar to control group
Notes: *Patients with STeMi undergoing primary PCi.
Abbreviation: N, number of patients.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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ischemic complications and bleeding after angioplasty 
compared with high-dose heparin.44 Subsequent pilot stud-
ies suggested that bivalirudin with planned or provisional 
abciximab may be at least as safe and effective as low-dose 
heparin plus abciximab during percutaneous coronary 
intervention.45,46 Similarly, in a randomized, open-labeled, 
phase III study (ACUITY) involving 13,819 patients with 
ACS in whom urgent or early intervention was planned, 
both bivalirudin plus a GP IIb/IIIa inhibitor and bivalirudin 
monotherapy were found to be superior to heparin plus GP 
IIb/IIIa inhibitor for the primary composite end points of MI, 
unplanned revascularization or death from any cause at 30 
days.47 The primary end point of major bleeding unrelated 
to coronary artery bypass graft surgery was significantly 
lower in patients receiving bivalirudin monotherapy com-
pared to those receiving heparin plus GP IIb/IIIa inhibitor 
after 30 days. In patients receiving bivalirudin plus a GP 
IIb/IIIa inhibitor, bleeding complications were superior to a 
regimen of heparin plus planned GP IIb/IIIa. At the 1-year 
follow-up, the composite end points of ischemia and all-cause 
  mortality was comparable among bivalirudin plus a GP IIb/
IIIa   inhibitor-, bivalirudin monotherapy-, and heparin plus 
a GP IIb/IIIa inhibitor-treated groups.
The Randomized Evaluation in PCI Linking Angiomax 
to Reduced Clinical events (REPLACE)-2 trial was among 
the first large-scale randomized, double-blind, active 
controlled trial designed to test the safety and efficacy of 
bivalirudin and provisional GP IIb/IIIa blockade during PCI 
compared with the standard practice of low-dose heparin 
plus planned GP IIb/IIIa blockade.48 The study comprised 
over 6,000 patients who were randomly assigned to receive 
intravenous   bivalirudin (0.75 mg/kg followed by 1.75 mg/kg 
per hour for the duration of PCI; n = 2,999), or heparin 
(65 U/kg) with planned GP IIb/IIIa inhibition (abciximab or 
eptifibatide; n = 3,011). All patients received daily aspirin 
and a thienopyridine for at least 30 days after PCI. There 
was no statistically significant difference in the primary 
end points of 30-day incidence of death, MI, urgent repeat 
revascularization, or in-hospital major bleeding between 
bivalirudin- and heparin-treated groups (9.2% vs 10.0%, 
respectively, P = 0.32). Similarly, the secondary composite 
end point was comparable between the two treatment groups. 
Provisional GP IIb/IIIa was administered in 7.2% of patients 
in the bivalirudin group. Notably, in-hospital major bleeding 
rates were significantly reduced in bivalirudin-treated groups 
(2.4% vs 4.1%, P , 0.01).
The encouraging results on the safety and efficacy of 
bivalirudin alone (as compared with heparin plus GP IIb/IIIa) 
observed in the REPLACE-2 trial have sparked interest in the 
use of this antithrombotic regimen in the setting of primary 
PCI in patients with ST-elevation acute MI. Results from the 
HORIZONS-AMI consisting of 3,602 patients with STEMI 
who were randomized to receive bivalirudin monotherapy and 
provisional GP IIb/IIIa inhibitors or heparin plus GP IIb/IIIa 
inhibitors demonstrated that bilivarudin monotherapy resulted 
in significantly reduced 30-day rates of major bleeding and 
net adverse clinical events (9.2% vs 12.1%; relative risk, 
0.76, P = 0.005), compared to heparin plus GP IIb/IIIa 
inhibitors (abciximab or eptifibatide) owing to a lower rate 
of major bleeding (4.9% vs 8.3%, P , 0.001).49 Treatment 
with bivalirudin alone, as compared with heparin plus 
GP IIb/IIIa inhibitors resulted in significantly lower 30-day 
rates of death from cardiac causes (1.8% vs 2.9%; relative 
risk, 0.62; 95% CI, 0.40 to 0.95; P = 0.03) and death from 
all causes (2.1% vs 3.1%; relative risk, 0.66; 95% CI, 0.44 
to 1.00; P = 0.047). There was an increased risk of acute 
stent thrombosis within 24 hours in the bivalirudin group but 
no significant increase was pre after 30 days. Glycoprotein 
IIb/IIIa inhibitors were administered in 7.2% of patients 
(129 patients) who were assigned to bivalirudin, in 47 because 
of a sustained absence of reflow after PCI, in 32 because of 
a giant thrombus after PCI, and in the rest for various other 
indications. It is speculated that the early increase in stent 
thrombosis with bivalirudin alone may be explained in part 
by adenosine diphosphate-induced platelet activation before 
maximal thienopyridine blockade by the P2Y12 receptor or 
by residual thrombin activity after the discontinuation of 
bivalirudin. Indeed, a clopidogrel loading dose   administered 
before the procedure might be inadequate to provide protective 
Table 5 Advantages of bivalirudin over heparin
Heparin Bivalirudin
•  Indirect thrombin inhibitor •    Direct thrombin inhibitor/Does not 
require cofactors
•    Nonspecific binding to:  
  Serine proteases  
  endothelial cells
•    Not inhibited by PF4 or anti-heparin   
proteins
•  Action dependent on AT •  Action independent of AT
•    Does not inhibit fibrin-bound  
protein
•  Inhibits fibrin-bound protein
•  Causes platelet aggregation •  Does not cause platelet aggregation
•  Variable PK-PD •    More predictable PK and  
anticoagulation effect
•  Risk of HIT •  Does not cause thrombocytopenia
Abbreviations:  AT,  antithrombin;  PK-PD,  pharmacokinetics-pharmacodynamics;   
HiT, heparin-induced thrombocytopenia; PF4, platelet factor4; PK, pharmacokinetics.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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antiplatelet aggregation, particularly in a subset of patients 
with clopidogrel resistance. Approximately one third of 
patients in each arm received clopidogrel 300 mg and two 
thirds received a 600 mg   loading dose. Whether   pretreatment 
with more rapidly acting and potent   thienopyridine agent 
(or higher loading dose regimen of clopidogrel), or a longer 
course of bivalirudin, or both, may reduce the incidence of 
early stent thrombosis without increasing the risk of bleed-
ing is unknown and remains to be studied. Nonetheless, it 
should be noted that there is currently no agent to reverse the 
antithrombotic effect of bivalirudin.
Analysis evaluating the predictive factors of acute, 
subacute, and late stent thrombosis after acute MI primary 
angioplasty in the HORIZONS-AMI trial revealed that the 
rates of acute stent thrombosis at 24 hours were significantly 
lower in those who received bivalirudin and pre-random-
ization heparin (bivalirudin + pre-randomization heparin) 
compared to those who did not receive pre-randomization 
heparin (bivalirudin, no pre-randomization heparin) [0.9% 
vs 2.6%, respectively, P = 0.006].
Bivalirudin trials and outcomes are summarized in 
Table 6.
Bivalirudin: current status
Currently available data suggest that bivalirudin may 
be considered as an alternative strategy to heparin plus 
GP IIb/IIIa inhibitors, particularly in patients at high risk for 
bleeding complications. However, its use is relatively con-
traindicated in patients with chronic total occlusion because 
there is currently no agent to reverse its antithrombotic 
effects. For elective PCI, bivalirudin monotherapy (with 
provisional GP IIb/IIIa for procedural complications) has 
emerged as the antithrombin of choice, providing similar 
protection from ischemic events as low dose UFH plus 
routine GP IIb/IIIa (or high dose UFH alone) with mark-
edly less bleeding.
Antithrombins current status
In STEMI patients undergoing primary PCI, the ACC/AHA 
guidelines recommend supportive anticoagulant therapy with 
unfractionated heparin (UFH) (Class I, LOE C) or bivalirudin 
(Class I, LOE B) in addition to aspirin and thienopyridine. 
Patients who have already been on UFH should receive 
additional boluses to maintain therapeutic activated clotting 
time, taking into account whether a GP IIb/IIIa receptor 
antagonist has been given. Patients who have not been given 
a GP IIb/IIIa should have a target ACT 250–300 seconds 
using a Hemotec device or target ACT 300–350 seconds 
using a Hemochron device. Patients who have been given a 
GP IIb/IIIa should have a target ACT of 200–250 seconds. 
Enoxaparin may be considered as an alternative to UFH 
(Class IIB). Bivalirudin may be administered with or without 
Table 6 Direct thrombin inhibitor trials and outcomes
Trial Study drug N 10 endpoints Outcomes/comments
ACUiTY Bivalirudin+GP iib/iiia
Bivalirudin monotherapy
Heparin (or enoxaparin)+ 
GP iib/iiia
2,609
2,619
2,561
Composite of death from  
any cause, Mi, or unplanned  
revascularization @ 30 days;  
major bleeding unrelated to CABG
Both bivalirudin regimen were
non-inferior to heparin  
(or enoxaparin) + GP iib/iiia
Lower major bleeding with  
bivalirudin monotherapy
Comparable composite of ischemia 
and all-cause mortality among  
3 groups at 1 yr
RePLACe-2 Bivalirudin+provisional  
GP iib/iiia
Low-dose heparin+ 
planned GP iib/iiia
2,999
3,011
Composite of death, Mi, urgent  
repeat revascularization, or  
in-hospital major bleeding @  
30 days
No difference between 2 groups
↓ in-hospital bleeding in
7% of bivalirudin group not given  
GP iib/iiia (P , 0.01)
HORiZONS- AMi Bivalirudin monotherapy+ 
provisional GP iib/iiia
Heparin+GP iib/iiia
1,800
1,802
Major bleeding; combined  
adverse Cv events (combination  
of major bleeding & MACe*)  
within 30 days or net adverse  
clinical events
Bivalirudin monotherapy versus 
Heparin GP iib/iiia (9.2% versus
12.1%, respectively, P = 0.005) 
(↓ major bleeding in bivalirudin group, 
P , 0.001) ↓ death from cardiac and 
non-cardiac causes (P = 0.03 and  
P = 0.047 respectively) ↑ stent 
thrombosis with bivalirudin ,24 h  
(P = 0.0007) but not by 30 days
*MACE: Major Adverse Cardiac Events defined as death, re-infarction, target vessel revascularization for ischemia and stroke.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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UFH and may be preferable in patients with high bleeding 
risk (Class IIA; LOE B).
In NSTEMI patients selected for early invasive 
  strategy, addition of UFH, enoxaparin, or bivalirudin 
may also be considered. Both UFH and enoxaparin 
have a Class I, LOE A indications. Bivalirudin have a 
Class I, LOE B indications. Despite the updated AHA/
ACC guidelines regarding   enoxaparin, it is not widely 
used for procedural   anticoagulation during PCI due to 
the lack of a rapid bedside assay for monitoring its anti-
coagulative effects. Current data do not support a role for 
fondaparinux during PCI. For patients undergoing PCI 
with prior fondaparinux treatment, additional intravenous 
therapy with an anticoagulant with anti-IIa   activity should 
be administered.
Antithrombotic dosing and bleeding risks
The advent of potent antiplatelet and antithrombin agents 
over the past decade has resulted in significant improvement 
in reducing ischemic events in ACS patients. However, the 
use of antiplatelet and antithrombotic combination therapy, 
often in the settings of PCI, has led to an increase in the risk 
of bleeding. More importantly, such complications have 
been reported to be associated with increased mortality, 
myocardial infarction, and stroke risks.50–52 The CRUSADE 
registry database revealed that over 42% of patients with 
NSTEMI received one or more antithrombotic agents above 
the recommended dosage range. Excessive dosing and 
the number of agents administered in excess were found to 
be directly related to the risks of bleeding. Suggested factors 
associated with elevated bleeding risks included older age 
defined as age . 65 years, (particularly age . 75), female 
gender, chronic kidney disease, low body weight with 
increasing risk for every 5 kg decrease in weight, diabetes, 
and congestive heart failure. Proper dosing requires adjust-
ments based on body weight and renal function.53 Similar to 
the CRUSADE registry study results, numerous researchers 
have demonstrated that older age, female gender, low body 
mass weight, and chronic kidney disease are powerful pre-
dictors of bleeding complications.51,52 Other suggested risk 
factors include invasive procedures and baseline hemoglobin 
and hematocrit values. In addition to the patient’s baseline 
characteristics, the type, degree, and rapidity of   anticoagulation 
and platelet inhibition may play a contributory role in 
bleeding complications.52 Assessment of bleeding risks 
should be an integral part of risk stratification for ACS. 
The judicious balance between antithrombotic effect and 
risk of bleeding may further improve clinical outcomes of 
patients with ACS.
Summary
Percutaneous coronary intervention (PCI), including 
angioplasty and coronary stent placement, is currently the 
treatment of choice for patients with ACS and STEMI. In such 
patients, aspirin and clopidogrel dual therapy has remained 
the cornerstone of oral antiplatelet therapy.   Currently 
  available data support the use of high-dose clopidogrel 
  loading (600 mg) if given . 2–6 hours pre-PCI, and standard 
loading dose (300 mg) if given . 6–12 hours pre PCI. For 
elective PCI, clopidogrel 75 mg daily should be continued for 
a variable period depending in part on stent type. For patients 
with ACS, clopidogrel should be continued at least one year 
regardless of the stent type. Studies in which the safety and 
efficacy of higher loading and maintenance dose regimen 
of clopidogrel versus standard dose regimen and high-dose 
(.300 mg) vs low-dose aspirin (,100 mg) were evaluated 
favor administration of high dose aspirin and high loading 
and maintenance dose of clopidogrel in ACS patients under-
going PCI. There was no statistically significant difference 
in cardiovascular end point among patients taking high- vs 
low-dose aspirin with the exception of the high-dose aspirin 
and high-dose clopidogrel PCI supgroup. Due to the wide 
interindividual variability in the response to clopidogrel, a 
newer third generation thienopyridine drug was developed. 
The TRITON-TIMI 38 trial involving moderate- to high-
risk patients with ACS undergoing PCI demonstrated that 
prasugrel was superior to clopidogrel in reducing major 
adverse cardiac events although its use was associated with 
an increased risk of TIMI major hemorrhage in a subset 
of patients. Prasugrel was recently approved by the FDA 
for use in ACS patients undergoing PCI as an alternative 
to clopidogrel. Its use may be preferable to clopidogrel in 
patients with high thrombus burden or high risk for throm-
bus formation. Results from the PLATO trial demonstrated 
that ticagrelor was also superior to clopidogrel in reducing 
ischemic events but without an increased risk of bleeding. 
Ticagrelor, however, has not been approved by the FDA for 
use in ACS patients.
In addition to dual antiplatelet therapy, patients with ACS 
should be given supportive anticoagulant therapy in the early 
periprocedural period. Administration of UFH is still regarded as 
the gold standard antithrombotic therapy. Bivalirudin overcomes 
several limitations of heparin and may be considered as an alter-
native strategy to UFH plus GP IIb/IIIa inhibitors particularly in Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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patients at risk for bleeding   complications. However, its use is 
relatively contraindicated in patients with chronic total occlusion 
because there is   currently no agent to reverse the antithrombotic 
effect of bivalirudin. Bivalirudin should be used with   caution 
in patients without UFH or clopidrogel pretreatment due to 
increased risk of acute stent thrombosis. Although enoxaparin 
has been suggested to be superior to UFH and its use obviates the 
need for laboratory monitoring, enoxaparin is associated with 
increased bleeding complications. The routine recommendation 
of enoxaparin use in high-risk patients undergoing PCI awaits 
further studies. Similar to enoxaparin, fondaparinux causes 
less interindividual   variation in therapeutic response than UFH 
and appears to be an attractive therapeutic option in patients 
undergoing PCI. Nevertheless, fondaparinux has been shown 
to result in higher rates of coronary complications compared to 
UFH. Currently available data does not support a role for fonda-
parinux during PCI. The use of fondaparinux and adjunctive 
UFH during PCI has been suggested to provide the beneficial 
effect of reducing the risk of catheter thrombosis and related 
complications without an increase in clinical complications or 
major bleeds. However, further studies are needed. Suggested 
antithrombotic strategies in patients undergoing PCI for ACS 
or STEMI in the contemporary era of early invasive coronary 
intervention are summarized in Figure 2.
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